Welcome to episode 459 of the AI in Action podcast, the show where we break down the hype and explore the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives.

Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts to showcase the excellent work that is being done within AI in North America and Europe.

Today’s guest is Laurens Kruidenier, Chief Scientific Officer at Cellarity, a Flagship Pioneering company. Launched in 2019, Cellarity are fundamentally redesigning the way drugs are created. Unlike conventional drug discovery, which attempts to reduce disease to single causal targets, Cellarity’s approach leverages a deep understanding of disease biology. The company’s approach is a more robust path for drug creation because they target the whole cell—the complex, networked living system that is the ultimate integrator of human biology.

The Cellarity platform provides critical insights into cellular dysfunction and reveals new biology that they can use to treat disease. This vantage point opens treatment avenues in countless diseases, including many that have been overlooked or have been too complex to resolve with traditional approaches. With programs in hematology, immuno-oncology and metabolism, Cellarity are pioneering a new generation of medicines.

In the episode, Laurens will talk about:

Interesting roles he’s held over the years 

The mission they are working on at Cellarity 

How they use AI and computational methods in drug discovery 

How the team is structured for success 

What excites him for the near future 

Why to consider a career with Cellarity 

To find out more about all the great work happening at Cellarity, check out the website www.cellarity.com or follow them on LinkedIn and Twitter @cellaritybio. You can also connect with Laurens directly on LinkedIn.

If you’re interested in exploring our latest Data Science &ML jobs, check out our live vacancies or upload your resume today to keep up to date with all the latest opportunities.

Subscribe to The Alldus Podcast: